BUCCI, Marco
 Distribuzione geografica
Continente #
NA - Nord America 6.785
EU - Europa 5.309
AS - Asia 4.219
Continente sconosciuto - Info sul continente non disponibili 503
SA - Sud America 438
AF - Africa 68
OC - Oceania 6
Totale 17.328
Nazione #
US - Stati Uniti d'America 6.636
SG - Singapore 1.794
IT - Italia 1.436
CN - Cina 1.123
IE - Irlanda 581
DE - Germania 527
SE - Svezia 492
UA - Ucraina 487
FR - Francia 465
RU - Federazione Russa 460
VN - Vietnam 394
GB - Regno Unito 379
BR - Brasile 343
TR - Turchia 342
FI - Finlandia 205
IN - India 203
HK - Hong Kong 97
CA - Canada 80
BD - Bangladesh 61
PL - Polonia 54
ES - Italia 44
MX - Messico 41
NL - Olanda 40
AR - Argentina 37
JP - Giappone 29
BE - Belgio 26
ID - Indonesia 24
ZA - Sudafrica 24
MY - Malesia 23
AT - Austria 20
EC - Ecuador 19
IQ - Iraq 19
KR - Corea 15
VE - Venezuela 15
CH - Svizzera 13
IL - Israele 13
IR - Iran 13
LT - Lituania 12
PK - Pakistan 12
CO - Colombia 11
EG - Egitto 11
GR - Grecia 11
AL - Albania 9
CZ - Repubblica Ceca 9
TH - Thailandia 9
EU - Europa 8
KE - Kenya 8
SA - Arabia Saudita 8
JM - Giamaica 7
PH - Filippine 7
UZ - Uzbekistan 7
ET - Etiopia 6
AU - Australia 5
MA - Marocco 5
PT - Portogallo 5
SI - Slovenia 5
AE - Emirati Arabi Uniti 4
CL - Cile 4
DK - Danimarca 4
EE - Estonia 4
LB - Libano 4
PY - Paraguay 4
TN - Tunisia 4
TT - Trinidad e Tobago 4
KZ - Kazakistan 3
QA - Qatar 3
RO - Romania 3
SK - Slovacchia (Repubblica Slovacca) 3
TW - Taiwan 3
BG - Bulgaria 2
CG - Congo 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
DZ - Algeria 2
HN - Honduras 2
HU - Ungheria 2
JO - Giordania 2
KG - Kirghizistan 2
LV - Lettonia 2
MD - Moldavia 2
NO - Norvegia 2
PA - Panama 2
PE - Perù 2
PR - Porto Rico 2
RS - Serbia 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AG - Antigua e Barbuda 1
AO - Angola 1
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CU - Cuba 1
GD - Grenada 1
GE - Georgia 1
GT - Guatemala 1
MC - Monaco 1
MK - Macedonia 1
Totale 16.825
Città #
Singapore 1.303
Chandler 721
San Jose 721
Jacksonville 568
Dublin 562
Ashburn 486
Dallas 384
Beijing 310
Munich 289
Council Bluffs 266
Princeton 254
Southend 222
Izmir 197
Los Angeles 193
New York 163
The Dalles 163
Nanjing 157
Santa Clara 154
Ho Chi Minh City 136
Ann Arbor 119
Wilmington 111
Pescara 106
Helsinki 104
Hanoi 99
Dearborn 97
Cambridge 93
Chieti 93
Milan 92
Hong Kong 79
Boardman 72
Tongling 70
Nanchang 63
Altamura 62
Rome 62
Moscow 53
São Paulo 51
Houston 48
Buffalo 45
Phoenix 45
Orem 44
Woodbridge 40
Columbus 37
Redondo Beach 37
Shenyang 35
Brooklyn 32
Warsaw 32
Denver 31
Hebei 31
Tianjin 31
Washington 31
Foggia 30
Hefei 27
London 26
Atlanta 25
Chennai 25
Chicago 25
Nuremberg 25
Tokyo 25
Brussels 24
Da Nang 24
Jinan 23
Montreal 23
Frankfurt am Main 22
Toronto 21
Boston 20
Haiphong 19
Kunming 19
Mexico City 19
Poplar 19
Stockholm 19
Bologna 18
Florence 18
Amsterdam 17
Norwalk 17
Johannesburg 16
Manchester 16
Zhengzhou 16
Naples 15
Turku 15
Grevenbroich 14
Hangzhou 14
Rio de Janeiro 14
Biên Hòa 13
Ningbo 13
Seattle 13
Auburn Hills 12
Changsha 12
Jiaxing 12
Mumbai 12
Orange 12
San Francisco 12
Guangzhou 11
Seoul 11
Bari 10
Kraków 10
Kuala Lumpur 10
Philadelphia 10
San Mateo 10
Shanghai 10
Taizhou 10
Totale 10.047
Nome #
Indici di rigidità arteriosa e rischio cardiovascolare globale: risultati da una popolazione abruzzese in prevenzione primaria 558
Comparison between Dutch Lipid Clinic Network (DLCN) criteria, Simon Broome register group (SB) and US MedPed Program diagnostic performance in a pediatric cohort from LIPIGEN study population: preliminary data. 346
MicroRNA profiling in migraine without aura: Pilot study 258
Rosuvastatin reduces Matrix Metalloproteinase (MMP)-9 and Plasminogen Activator Inhibitor (PAI)-1 expression via a microRNA-dependent pathway 257
The diagnostic performance of the Italian Society for the Study of Atherosclerosis (SISA)-modified Dutch Lipid Clinic Network (DLCN) criteria in a pediatric cohort from LIPIGEN study population: preliminary data 231
A unique microRNA signature associated with plaque instability in humans. 212
(Dis)-agreement among Cardiovascular Risk Calculators in clinical practice 187
Long-term Positivity to SARS-CoV-2: A Clinical Case of COVID-19 with Persistent Evidence of Infection 179
Linee guida cliniche per la prevenzione della cardiopatia ischemica nella ipercolesterolemia familiare: una patologia sotto-diagnosticata e sotto-trattata. Consensus. 174
A short-term vs a long-term infusion plan. A 20-week, European randomized trial. Analysis of efficacy and costs. 170
Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteases activity 170
VALUTAZIONE FUNZIONALE DELL'ATLETA: RAPPORTI TRA VO2 MAX E COMPOSIZIONE CORPOREA 169
A case of coinfection with SARS-COV-2 and Cytomegalovirus in the Era of Covid-19 169
Differences in blood pressure according to body position (supine, Fowler’s and sitting) in hypertensive subjects 167
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study 167
Bioequivalence study of two tablet formulations of ramipril in healthy volunteers 165
Uneven accuracy of home blood pressure measurement: a multi-centric survey 163
OVEREXPRESSION OF TOLL LIKE RECEPTOR 4 AS A BASIS OF CYCLOOXYGENASE 2-DEPENDENT ATHEROSCLEROTIC PLAQUE INSTABILITY IN HUMANS. 162
Pressure and microcirculatory effects of treatment with lercanidipine in hypertensive patients and in vascular patients with hypertension 159
A unique microRNA signature associated with ischemic stroke in humans 159
Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control 158
Overexpression of microRNA-145 in atherosclerotic plaques from hypertensive patients 157
24-months follow-up to assess the efficacy and tolerability of evolocumab in a young patient with chronic and progressive ischemic arteriopathy 157
Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. 152
Ipertensione arteriosa ed algosensibilità muscolare 148
[Controllo dei fattori di rischio cardiovascolare nella comune pratica clinica in un campione di pazienti in prevenzione secondaria rappresentativo della popolazione abruzzese] 147
High dose rosuvastatin increases ABCA1 transporter in human atherosclerotic plaques in a cholesterol-independent fashion 146
Angiotensin II Blockade and Total Cardiovascular Risk. Beyond Blood Pressure Reduction. 145
MicroRNA profiling reveals new potential modulators of insulin-resistance and cardiovascular risk in type 2 diabetes 145
Efficacy of a nurse-led email reminder program for cardiovascular prevention risk reduction in hypertensive patients: a randomized controlled trial. 144
ABCA-1 expression is reduced in atherosclerotic plaques from hypertensive patients: a new potential link between hypertension and atherosclerosis 142
Effect of Rosuvastatin on MicroRNAs expression in human atherosclerotic plaques: results from Quasar Study 142
ATP-binding cassette transporter A1 (ABCA1) overexpression in hypercholesterolemic plaques: a potential molecular explanation 141
Subcutaneous adipose tissue elastosonography in obese patients: a preliminary report 141
[European trial of PGE1 alpha cyclodextrin. Short-term vs. long-term therapy in intermittent claudication] 140
Risultati immediati ed a lungo termine della rivascolarizzazione coronarica con PTCA con carattere ad autoperfusione vs PTCA con impianto di stent intracoronarico. 139
COVID-19 and RAS: Unravelling an Unclear Relationship 138
A case of coinfection with SARS-Cov-2 and cytomegalovirus in the era of Covid-19. 138
Association between 5-lipoxygenase expression and plaque instability in humans. 137
Prescription of ACE-Is/ARBs in patients with cardio-renal disease: a multicenter retrospective cohort study from the REPOSI registry 136
Overexpression of ABCA1 in human plaques exposed to hypercholesterolemia: the role of microRNA modulation 136
Improvement of Inflammation and Pain after Three Months’ Exclusion Diet in Rheumatoid Arthritis Patients 136
Duration of COVID-19: Data from an Italian Cohort and Potential Role for Steroids 135
Total triterpenic fraction of Centella asiatica in chronic venous insufficiency and in high-perfusion microangiopathy. 134
MicroRNA profiling reveals new potential modulators of insulin-resistance in type 2 Diabetes 134
ABCA-1 Expression is reduced in atherosclerotic plaques of hypertensive patient: a new link between hypertension and atherosclerosis 133
Evaluation of treatment of diabetic microangiopathy with total triterpenic fraction of Centella Asiatica: a clinical prospective randomized trial with a microcirculatory model. 132
PGE(1) treatment of severe intermittent claudication (short-term versus long-term, associated with exercise)--efficacy and costs in a 20-week, randomized trial 132
La gestione del profilo lipidico nei pazienti in prevenzione secondaria sul territorio: lo studio ELL 130
The (K+)ey of the problem 130
[ANALYSIS OF COSTS AND RESULTS OF PROSTAGLANDIN (PGE1 ALPHA-CYCLODESTRIN) THERAPY OF PERIPHERAL ARTERIAL DISEASES] 130
LDL-Apheresis abruzzo network: an old-new opportunity for the management of patients at high cardiovascular risk. 129
Single coronary artery with a right origin: angiography identification of the R-II subgroup] 128
uFollow-Up clinico di un gruppo di pazienti sottoposti a PTCA con impianto di stent intracoronarico. 127
Nomograms used to define the short-term treatment with PGE(1) in patients with intermittent claudication and critical ischemia. The ORACL.E (Occlusion Revascularization in the Atherosclerotic Critical Limb) Study Group. The European Study. 127
L’automisurazione domiciliare della pressione: istruzioni per l’uso e sua utilità nel paziente anziano 127
Total triterpenic fraction of Centella asiatica in the treatment of venous hypertension: a clinical, prospective, randomized trial using a combined microcirculatory model. 126
PROGETTO DI SCREENING SU 24.000 SOGGETTI IN ETA' SCOLARE DELL'OBBLIGO DELLA PROVINCIA DI PESCARA. DATI PRELIMINARI. 126
La stratificazione del rischio di sviluppare Diabete Mellito come strumento di diagnosi precoce: lo studio DIGA 125
DISAGREEMENT AMONG THE MAIN ALGORITHMS FOR CARDIOVASCULAR RISK ESTIMATION IN PATIENTS STRATIFICATION AND IN THEIR CORRELATION WITH ARTERIAL STIFFNESS 125
Reduced TIA-1 expression in vulnerable atherosclerotic plaques as a basis of cyclooxygenase-2-dependent plaque instability in humans. 124
MicroRNA profiling reveals new potetial modulators of insulin resistance and cardiovascular risk in type 2 diabetes 124
Impact of hypertension on somatic pain sensitivity in chronic headache 124
Arterial stiffness and global cardiovascular risk: results from a primary prevention population from Abruzzo (Italy) 123
Ensuring Longer Life Study. A new model for an integrated management of patients at high cardiovascular risk. 122
Hypertension is a determinant of ABCA1 expression in atherosclerotic plaques from hypercholesterolemic patients 121
Cardiovascular risk factor control in common clinical practice in a sample of patients in secondary prevention representative of the Abruzzo population 121
Artrite reumatoide ed aumentato rischio cardiovascolare: impatto delle differenti terapie farmacologiche
 [Rheumatoid arthritis and increased cardiovascular risk: role of the different pharmacological therapies] 120
Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes 119
Oral Porphyromonas gingivalis and Fusobacterium nucleatum Abundance in Subjects in Primary and Secondary Cardiovascular Prevention, with or without Heterozygous Familial Hypercholesterolemia 119
Plasma microRNA signature associated with retinopathy in patients with type 2 diabetes 117
HUR protein contributes to modulation of angiotensin ii type 1 receptor expression in human atherosclerotic plaque. 116
HuR protein as potential modulator of angiotensin II type 1 receptor expression in human atherosclerotic plaque. 115
From Endothelium to Lipids, Through microRNAs and PCSK9: A Fascinating Travel Across Atherosclerosis 115
Treatment of Diabetic Microangiopathy and Edema with Total Triterpenic Fraction of Centella Asiatica: A Prospective, Placebo-Controlled Randomized Study. 114
Cholesterol and COVID-19: Findings from lipid profile of patients with SARS-COV-2 infection 114
[Reduction of cardiovascular morbidity/mortality in arteriopathies treated ith PGE1 alpha-cyclodextrin] 113
Cardiovascular risk awareness: what does patient feel? 113
Microcirculatory Effects of Total Triterpenic Fraction of Cenetlla asiatica in Chronic Venous Hypertension: Measurement by Laser Doppler, TcPo2-CO2, and Leg Volumetry 112
Cost-effectiveness of statins in primary and secondary prevention of cardiovascular event 111
Muscle pain sensitivity in hypertensive patients with and without chronic pain 111
Possible indication of coronary risk trough discriminant functions. 110
Hypertension modulates miR-145 expression in human atherosclerotic plaques 110
Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: a 10 year follow-up study (the CAFES-CAVE Study). 109
Oxygen-free radical decrease in hypertensive patients treated with lercanidipine 109
Effect of evolocumab or ezetimibe added to moderate- Or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: The LAPLACE-2 randomized clinical trial 109
Long-term positivity to SARS-Cov-2: a clinical case of Covid-19 with persistent evidence of infection 108
Increase in Echogenicity of Echolucent Carotid Plaques After Treatment with Total Triterpenic Fraction of Centella Asiatica: A Prospective, Placebo-Controlled, Randomized Trial. 106
Effects of lifestyle treatment on patients with metabolic syndrome and non-alcoholic hepatic steatosis evaluated with an ultrasonographic and elastographic approach 105
Correlation between Dutch lipid score and genetic diagnosis of FH in pediatric patients 105
An atypical etiology of ARDS: the importance of a careful eye in the evaluation. 104
Endogenous PCSK9 may influence circulating CD45NEG/CD34BRIGHT and CD45NEG/CD34BRIGHT/CD146NEG cells in patients with type 2 Diabetes Mellitus 104
HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial. 103
PROGETTO DI SCREENING SU 24OOO SOGGETTI IN ETA' SCOLARE DELL'OBBLIGO DELLA PROVINCIA DI PESCARA. DATI PRELIMINARI 103
Effects of the total triterpenic fraction of Centella asiatica in venous hypertensive microangiopathy: a prospective, placebo-controlled, randomized trial 102
Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN) 102
Efficacy of Lomitapide in the Treatment of Familial Homozygous Hypercholesterolemia: Results of a Real-World Clinical Experience in Italy 102
Cardiovascular morbidity/mortality modified by the use of FGE1 alpha-cyclodextran and calcium heparin in patients with severe vascular diseases 101
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events 101
A drug induced autoimmune hemolytic anemia: a case report. 100
Totale 14.178
Categoria #
all - tutte 67.409
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.409


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022690 0 0 22 153 39 14 28 39 62 29 122 182
2022/20232.129 165 256 119 223 214 414 130 159 274 44 70 61
2023/20241.188 82 44 75 40 85 333 225 44 35 64 25 136
2024/20252.775 133 449 356 74 103 144 217 158 355 144 299 343
2025/20265.535 485 231 618 705 563 348 939 296 558 441 241 110
2026/2027475 134 304 37 0 0 0 0 0 0 0 0 0
Totale 17.328